Home » Stocks » Selecta Biosciences

Selecta Biosciences, Inc. (SELB)

Stock Price: $2.57 USD -0.04 (-1.53%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 275.36M
Revenue (ttm) 6.65M
Net Income (ttm) -70.58M
Shares Out 107.14M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $2.57
Previous Close $2.61
Change ($) -0.04
Change (%) -1.53%
Day's Open 2.62
Day's Range 2.55 - 2.63
Day's Volume 443,538
52-Week Range 1.28 - 4.83

More Stats

Market Cap 275.36M
Enterprise Value 241.95M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 107.14M
Float 81.85M
EPS (basic) -1
EPS (diluted) -0.97
FCF / Share -0.49
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.30M
Short Ratio 6.72
Short % of Float 10.25%
Beta 1.28
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 41.38
PB Ratio 31.26
Revenue 6.65M
Operating Income -66.21M
Net Income -70.58M
Free Cash Flow -47.79M
Net Cash 33.41M
Net Cash / Share 0.31
Gross Margin -307.66%
Operating Margin -995.00%
Profit Margin n/a
FCF Margin -718.21%
ROA -60.94%
ROE -2,077.15%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(217.90% upside)
Current: $2.57
Target: 8.17
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-59.13-65.93-63.99-42.75-31.32-18.44
Net Income-55.35-65.34-65.32-36.21-25.17-12.88
Shares Outstanding45.5522.3920.4310.492.152.09
Earnings Per Share-1.22-2.92-3.20-3.89-15.13-7.84
Operating Cash Flow-51.44-59.16-52.03-19.76-22.46-12.69
Capital Expenditures0.08-0.79-0.73-0.58-1.16-0.23
Free Cash Flow-51.36-59.95-52.76-20.34-23.63-12.91
Cash & Equivalents90.1737.4096.6484.5436.9118.94
Total Debt19.2821.3921.0412.0411.867.40
Net Cash / Debt70.9016.0275.6072.4925.0611.54
Book Value8.40-5.4251.8154.96-116-87.76
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Selecta Biosciences, Inc.
Country United States
Employees 39
CEO Carsten Brunn

Stock Information

Ticker Symbol SELB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SELB
IPO Date June 22, 2016


Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. The company has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., and Sarepta Therapeutics, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.